CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 53 enrolled
Drug / intervention
N-acetylcysteine (NAC) +1 moredrug
Likely dose
N-acetylcysteine (NAC) 600mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00552786
NCT00552786Phase 2Completed
CompareCT.gov

Antioxidation Medication for Noise-induced Hearing Loss

National Taiwan University Hospital·interventional·Posted Nov 2, 2007·Updated Jul 27, 2010

In Brief

A Phase 2 clinical trial evaluating N-acetylcysteine (NAC) and glucose for Hearing Loss. Completed, enrolled 53 participants across 1 site.

Detailed Summary

This study will examine whether oral intake of 1200mg N-Acetylcysteine/day will prevent temporary threshold shift in hearing among workers exposed to noise

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHearing Loss
CountriesTaiwan
CollaboratorsInstitute of Occupational Safety and Health, Taiwan, Municipal Hospital of Tainan, Taiwan

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2, 2007
Enrollment StartNov 1, 2007
Primary CompletionJan 1, 2008
Study CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 18.7 years ago

Interventions

N-acetylcysteine (NAC)drug

600mg twice daily for 2 weeks

glucosedrug

1 gm glucose capsule